This paper is only available as a PDF. To read, Please Download here.
Ovarian hyperstimulation syndrome (OHSS) is a serious iatrogenic complication of ovarian stimulation. It is feasible to identify patients at risk, modify stimulation strategies to ameliorate risk, and initiate out-patient treatments that alter disease pathophysiology to reduce disease severity. Mitigation of OHSS risk and severity, through innovative approaches prior to treatment, during treatment and after treatment should now be standard care. This review summarizes recent developments and provides recommendations on the prevention and treatment of OHSS.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Thrombosis Research
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Prevention and treatment of moderate and severe ovarian hyperstimulation syndrome: a guideline.Fertil Steril. 2016; 106: 1634-1647
- Consensus statement on prevention and detection of ovarian hyperstimulation syndrome.Aust N Z J Obstet Gynaecol. 2015; 55: 523-534
- No. 5 G-tg. Ovarian Hyperstimulation Syndrome, Management.
- Ovarian hyperstimulation syndrome: review and new classification criteria for reporting in clinical trials.Hum Reprod. 2016; 31: 1997-2004
- Targeting the vascular endothelial growth factor system to prevent ovarian hyperstimulation syndrome.Hum Reprod Update. 2008; 14: 321-333
- Factors associated with ovarian hyperstimulation syndrome (OHSS) and its effect on assisted reproductive technology (ART) treatment and outcome.Fertil Steril. 2010; 94: 1399-1404
- Technical and performance characteristics of anti-Mullerian hormone and antral follicle count as biomarkers of ovarian response.Hum Reprod Update. 2014
- Gonadotrophin-releasing hormone antagonists for assisted reproductive technology.Cochrane Database Syst Rev. 2016; 4 (Cd001750)
- Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol: RCT including 1050 first IVF/ICSI cycles.Hum Reprod. 2016; 31: 1253-1264
- Oocyte number as a predictor for ovarian hyperstimulation syndrome and live birth: an analysis of 256,381 in vitro fertilization cycles.Fertil Steril. 2014; 101: 967-973
- Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimullerian hormone-stratified, dose–response trial in women undergoing in vitro fertilization/intracytoplasmic sperm injection.Fertil Steril. 2014; 102 (40.e5): 1633
- Individualized versus conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 non-inferiority trial.Fertil Steril. 2016; (Nov 22)https://doi.org/10.1016/j.fertnstert.2016.10.033
- Pharmacologic Interventions in Preventing Ovarian Hyperstimulation Syndrome: A Systematic Review and Network Meta-Analysis.Sci Rep. 2016; 6: 19093
- Low-dose aspirin therapy to prevent ovarian hyperstimulation syndrome.Fertil Steril. 2010; 93: 2281-2284
- Effect of low-dose aspirin therapy on implantation rate in women undergoing in-vitro fertilization cycles.Saudi Med J. 2007; 28: 732-736
- Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome.Cochrane Database Syst Rev. 2014; (Cd006105)
- A short course of metformin does not reduce OHSS in a GnRH antagonist cycle for women with PCOS undergoing IVF: a randomised placebo-controlled trial.Hum Reprod. 2016; 31: 2756-2764
- Gonadotropin-releasing hormone antagonist and metformin for treatment of polycystic ovary syndrome patients undergoing in vitro fertilization-embryo transfer.Gynecol Endocrinol. 2006; 22: 235-238
- The science behind 25 years of ovarian stimulation for in vitro fertilization.Endocr Rev. 2006; 27: 170-207
- GnRH agonist for triggering of final oocyte maturation: time for a change of practice?.Hum Reprod Update. 2011; 17: 510-524
- Consistent high clinical pregnancy rates and low ovarian hyperstimulation syndrome rates in high-risk patients after GnRH agonist triggering and modified luteal support: a retrospective multicentre study.Human Reprod. 2013; 28: 2529-2536
- Impact of GnRH agonist triggering and intensive luteal steroid support on live-birth rates and ovarian hyperstimulation syndrome: a retrospective cohort study.J Ovarian Res. 2013; 6: 93
- Elective cryopreservation of all pronuclear oocytes after GnRH agonist triggering of final oocyte maturation in patients at risk of developing OHSS: a prospective, observational proof-of-concept study.Human Reprod. 2007; 22: 1348-1352
- An OHSS-Free Clinic by segmentation of IVF treatment.Human Reprod. 2011; 26: 2593-2597
- Risk factors for a suboptimal response to gonadotropin-releasing hormone agonist trigger during in vitro fertilization cycles.Fertil Steril. 2015; 104: 637-642
- GnRH agonist with low-dose hCG (dual trigger) is associated with higher risk of severe ovarian hyperstimulation syndrome compared to GnRH agonist alone.J Assist Reprod Genet. 2016; 33: 1175-1184
- Cabergoline for the prevention of ovarian hyperstimulation syndrome: systematic review and meta-analysis of randomized controlled trials.Fertil Steril. 2014; 101: 664-675
- Calcium infusion for the prevention of ovarian hyperstimulation syndrome: a double-blind randomized controlled trial.Fertil Steril. 2015; 103: 101-105
- An ounce of prevention: outpatient management of the ovarian hyperstimulation syndrome.Fertil Steril. 2000; 73: 821-824
- Venous thromboembolism in relation to in vitro fertilization: an approach to determining the incidence and increase in risk in successful cycles.Fertil Steril. 2012; 97: 95-100
- Incidence of pulmonary and venous thromboembolism in pregnancies after in vitro fertilisation: cross sectional study.BMJ. 2013; 346 (e8632)
© 2017 Elsevier Ltd. Published by Elsevier Inc. All rights reserved.